System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Patrizia Chiusolo is an expert in Hematology at Agostino Gemelli University Polyclinic (Italy). As of October 2026, ScienceLeadR ranks Patrizia Chiusolo in the top 1% of experts worldwide for Stem Cell Transplantation, Cell Transplantation and Leukemia. Patrizia Chiusolo has authored 490 publications, the most recent in 2026, and is an investigator in 24 clinical trials, 9 of them ongoing. SLR score: 1,703 (community average: 125). How the SLR is computed.

LeadR Profile

Patrizia Chiusolo Agostino Gemelli University Polyclinic Italy
1 703 ScienceLeadR Reputation 1703

Unlock

Register Login
Network Map

Hematology

Subspecialties: Transplantation - Oncology - Immunology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1998 - 2026
Source: PubMed

Catholic University of the Sacred Heart

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 490

Citations

Citations: 7 848 1st author: 38 Last author: 32 Unique author: 1

Main journals

Blood 75
Bone Marrow Transplant 58
Haematologica 33
Am J Hematol 21
Mediterr J Hematol Infect Dis 21

Best Journals

J Clin Oncol 4
N Engl J Med 2
Eur Heart J 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.
PMID 42874102 — precursor cell lymphoblastic leukemia-lymphoma, disease-free survival, drug therapy, chemotherapy		N Engl J Med Top journal20260
Different treatment eras for relapsed and refractory primary mediastinal B-cell lymphoma patients: accessibility to CAR T cells is associated with a better prognosis in a pooled analysis of the REPRIME-FIL and the CART-SIE studies.
PMID 42779302 — cells, hematology, lymphoma, b-cell, lymphoma, therapeutics, b-lymphocytes, prognosis, salvage therapy, car-t cell		Haematologica20260
Independent validation of the International Metabolic Prognostic Index (CAR-IMPI) in patients with aggressive diffuse large B-cell lymphoma treated with CAR-T.
PMID 42747070 — cells, lymphoma, b-cell, lymphoma, lymphoma, large b-cell, diffuse, b-lymphocytes		Br J Haematol20260
Clinical Outcomes of Younger Adults With Philadelphia-Negative Acute Lymphoblastic Leukemia, Treated With A Pediatric-Like Regimen Based on the GIMEMA LAL1308 Protocol. A Campus ALL Study.
PMID 42708703 — precursor cell lymphoblastic leukemia-lymphoma, hematology, leukemia, therapeutics, survival rate		Eur J Haematol20260
Early deterioration and subsequent recovery of nursing complexity after CAR-T therapy: a prospective score-based analysis.
PMID 42701133 — nursing, bone marrow transplantation, recycling, therapeutics		Bone Marrow Transplant20260

Clinical Studies 24

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 5

By phase:

N/A 12
Phase 3 5
Phase 1/Phase 2 3
Phase 2 3
Phase 2/Phase 3 1

By status:

Recruiting 11
Completed 7
Active not recruiting 2
Not yet recruiting 2
Terminated 1
Unknown 1

By type:

Interventional 14
Observational 10

By Monocentric/Multicentric:

monocentric 7
multicentric2to4 1
multicentric5to9 1
multicentricup10 15

Main Topics

Cohort/Consortium Investigators 2

Ongoing Clinical Trials

9 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Phase 1 2 study of Enzomenib (DSP 5336) in Patients with Acute leukemia
2022-502741-10-00 — hematologic neoplasms, leukemia, mutation		Phase 1/Phase 2Recruiting2024
A phase 2 multicentric study to assess the efficacy and safety of maribavir treatment in hematopoietic stem cell transplant (HSCT) recipients with cytomegalovirus (CMV) infection with a medical condition that contraindicate the administration of ganciclovir valganciclovir or foscarnet and in those who discontinued first line preemptive therapy with ganciclovir valganciclovir or foscarnet due to toxicity or intolerance
2025-521074-34-00 — cells, safety, microscopy, electron, scanning transmission, cytomegalovirus infections, ganciclovir, stem cells, cytomegalovirus, foscarnet, transplants, therapeutics, hematopoietic stem cells, antiviral agents, infections, valganciclovir		Phase 2Recruiting2026
Prevalence Of Germline Gene Mutations In Patients With Myeloproliferative Neoplasms With Family History
NCT06923670 — research design, genes, thrombocythemia, essential, polycythemia vera, thrombocytosis, hematologic neoplasms, multiple endocrine neoplasia type 1, neoplasms, epithelial cell adhesion molecule, polycythemia, prevalence, myeloproliferative disorders, genes, apc, history, genes, brca1, mutation, primary myelofibrosis		N/ANot yet recruiting2025
Clinical Evaluation of the Scopio Cell Morphology Technology
NCT06574308 — cells, reading, bone marrow, blood, hematologic neoplasms, neoplasms, classification, blood cells, artificial intelligence, bone marrow cells		N/ANot yet recruiting2024
Master Framework For Relapse or Refractory Acute Myeloid Leukemia
NCT06459024 — leukemia, leukemia, myeloid, acute, leukemia, myeloid, therapeutics		N/ARecruiting2024

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS